149759-26-2

149759-26-2 structure

Name: LOE 908 HYDROCHLORIDE
Chemical Name: 2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)-2-phenyl-N,N-bis[2-(2,3,4-trimethoxyphenyl)ethyl]acetamide
CAS Number: 149759-26-2
Molecular Formula: C₄₁H₄₉ClN₂O₉
Molecular Weight: 749.28900
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2016-12-04 02:12:24
Modify Date: 2024-01-10 09:47:28
Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity[1].

Name	2-(6,7-dimethoxy-3,4-dihydroisoquinolin-1-yl)-2-phenyl-N,N-bis[2-(2,3,4-trimethoxyphenyl)ethyl]acetamide
Synonyms	unii-7j9zz971ao pinokalant loe 908

Description	Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity[1].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> TRP Channel Signaling Pathways >> Anti-infection >> SARS-CoV Research Areas >> Neurological Disease
In Vivo	Pinokalant significantly reduces cortical infarct volume from 33.8 mm3 to 24.5 mm3[1].
References	[1]. Christensen T, et al. The broad-spectrum cation channel blocker pinokalant (LOE 908 MS) reduces brain infarct volume in rats: a temperature-controlled histological study. Basic Clin Pharmacol Toxicol. 2005 Apr;96(4):316-24. [2]. Simard JM, et al. Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim Biophys Acta. 2007 Aug;1772(8):947-57. [3]. Serdar Durdagi, et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. 2020.